A

Axsome Therapeutics

AXSM

86.075
USD
-1.255
(-1.44%)
Market Open
Volume
7,266
EPS
0
Div Yield
0
P/E
-14
Market Cap
4,481,779,141
Related Instruments
A
ACAD
-0.020
(-0.11%)
19.000 USD
A
AVDL
0.135
(0.83%)
16.490 USD
C
CRBP
-0.500
(-0.84%)
59.160 USD
E
EOLS
1.660
(13.38%)
14.070 USD
E
ESPR
-0.13000
(-5.62%)
2.18500 USD
I
ITCI
0.260
(0.33%)
79.030 USD
K
KPTI
-0.06290
(-6.37%)
0.92380 USD
P
PRQR
-0.10000
(-5.24%)
1.81000 USD
S
SAGE
-1.21000
(-11.03%)
9.76000 USD
News

Title: Axsome Therapeutics

Sector: Healthcare
Industry: Biotechnology
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.